



DOCKET NO: 368-014

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
Kinam Park, et al.

Serial No: 09/975,800

Art Unit: Unassigned

Filed: October 11, 2001

Examiner: Unassigned

For: PHARMACEUTICAL APPLICATIONS:
OF HYDROTROPIC AGENTS, POLYMERS :
THEREOF, AND HYDROGELS THEREOF :

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:


In accordance with the provisions of 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is directed to the documents listed on the attached form PTO-1449. It is respectfully requested that the documents be expressly considered during the prosecution of this application, and that the documents be made of record therein and appear among the "References Cited" on any patent to issue therefor.

Inasmuch as the disclosures of U.S. Patent Nos. 4,933,643; 4,981,974; and 5,008,367 (Dandreaux et al.) are cumulative, only the last listed patent is enclosed. Inasmuch as the disclosures of U.S. Patent Nos. 4,946,967 and 4,987,210 (Login et al.) are cumulative, only the latter patent is enclosed. 37 CFR 1.98(c).


U.S. Serial No. 09/975,800

This Information Disclosure Statement is filed within three months of the filing date for this continued prosecution application (CPA) OR before the mailing date of a first Office Action on the merits. No certification or fee is required.

Respectfully submitted,


James H. Meadows, Ph.D.
Reg. No. 33,965

Correspondence Address
5355 Mira Sorrento Pl.
Suite 100
San Diego, CA 92121
Tel: 619-641-8228
Fax: 503-217-9394
Date: January 18, 2002

I, James H. Meadows, hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on 1/19/02 Signature 

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	09/975,800
Filing Date	October 11, 2001
First named Inventor	Kinam Park
Group Art Unit	
Examiner Name	
Attorney Docket Number	368-014

Sheet 2 of 3

OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS


Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T6
		NICOLAOU, K. et al. "Design, synthesis and biological activity of protaxols," Nature, 1993, 364: 464-466.	
		PENDRI, A., et al. "Antitumor activity of paclitaxel-2'-glycinate conjugated to poly(ethylene glycol): a water-soluble prodrug," Anti-Cancer Drug Design, 1998, 13: 387-395.	
		TAVARE, N. et al. "Solubilities of 6-aminopenicillanic acid and phenoxyacetic acid in hydrotrope solutions," J. Chem. Eng. Data, 1996, 41: 1196-1202.	
		MULLER, B. et al. "Effect of hydrotropic substances on the complexation of sparingly soluble drugs with cyclodextrin derivatives and the influence of cyclodextrin complexation on the pharmacokinetics of the drugs," J. Pharm. Sci., 1991, 80: 599-604.	
		GRAZIANO, G. "On the solvent isotope effect in hydrophobic hydration," J. Phys. Chem. B, 2000, 104: 9249-9254.	
		KUMAR, M. et al. "Effect of hydrotropes on solubility and mass transfer coefficient of methyl salicylate," J. Chem. Eng. Data, 2000, 45: 419-423.	
		SRINIVAS, V., et al. "When does the switch from hydrotropy to micellar behavior occur?" Langmuir, 1998, 14: 6658-6661.	
		DHARA, D. et al. "Effect of hydrotropes on the volume phase transition in poly(N-isopropylacrylamide) hydrogel," Langmuir, 1999, 15: 930-935.	
		SALEH, A., et al. "Solubilization of water by hydrotropic salts," J. Pharm. Sci., 1986, 75: 644-647.	
		COFFMAN, R., et al. "Effect of nicotinamide and urea on the solubility of riboflavin in various solvents," J. Pharm. Sci., 1996, 85: 951-954.	
		SERAJUDDIN, A. "Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs," J. Pharm. Sci., 1999, 88: 1058-1066.	
		ALKAN-ONYUKSEL, H. et al. "A mixed micellar formulation suitable for the parenteral administration of taxol," Pharm. Res., 1994, 11: 206-212.	
		SHARMA, A. et al. "Novel taxol formulations: preparation and characterization of taxol-containing liposomes," Pharm. Res., 1994, 11: 889-896.	
		MANI, S., et al. "Phase I clinical and pharmacokinetic study of oral 9-aminocamptothecin (NSC-603071)," Cancer Chemother. Pharm., 1998, 42: 84-87.	

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box →

+

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)

Sheet 3 of 3

Complete if Known

Application Number	09/975,800
Filing Date	October 11, 2001
First named Inventor	Kinam Park
Group Art Unit	
Examiner Name	
Attorney Docket Number	368-014



OTHER PRIOR ART-NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T6
		FORD, J. "The current status of solid dispersions," Pharm. Acta Helv., 1986, 61: 69-88.	
		LEUNG, S. et al., "Polymeric micellar paclitaxel phosphorylates bcl-2 and induces apoptotic regression of androgen-independent LNCaP prostate tumors," The Prostate, 2000, 44: 156-163.	
		CHIOU, W., et al., "Pharmaceutical Applications of Solid Dispersion Systems," J. Pharm. Sci., 1971, 60: 1281-1302.	
		FLOYD, A. G. et al. "7. Injectable emulsions and suspensions." <u>Pharmaceutical Dosage Forms: Disperse Systems</u> , 1998, pp. 261-318, Vol. 2, Marcel Dekker, Inc., New York, NY	
		MACHERAS, P., et al., "4. Supply of the gastrointestinal fluids with drug," <u>Biopharmaceutics of Orally Administered Drugs</u> , 1995, pp. 35-87, Ellis Horwood, New York, NY.	
		LOBENBERG, R., et al., "9. Solubility as a limiting factor to drug absorption," <u>Oral Drug Absorption. Prediction and Assessment</u> , pp. 137-153, Marcel Dekker, Inc., New York, NY	
		MULLER, R. H. et al., "9. Nanosuspensions," <u>Emulsions and Nanosuspensions for the Formulation of Poorly Soluble Drugs</u> , 1998, pp. 149-174, Medpharm Scientific Publ., Stuttgart, Germany	
		HABIB, M. J., et al. "2. Fundamentals of solid dispersions," <u>Pharmaceutical Solid Dispersion Technology</u> , 2001, pp. 7-35, Technomic Pub. Co., Inc., Lancaster, PA	
		MARTIN, A., et al., <u>Physical Pharmacy. Physical Chemical Principles in the Pharmaceutical Sciences</u> , 1993, pp.272-273, 4 th ed, Lea & Febiger, Philadelphia, PA	
		YALKOWSKY, S., <u>Solubility & Solubilization in Aqueous Media</u> , 1999, p. 429, ACS Publ., Washington, DC	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.